Crossmark

Feasibility study of using high‐throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment

Published Online: 2019-12-30

Published Print: 2019-12

Authors

Skaga, Erlend https://orcid.org/0000-0003-3942-3492
Kulesskiy, Evgeny

Brynjulvsen, Marit

Sandberg, Cecilie J.

Potdar, Swapnil

Langmoen, Iver A.

Laakso, Aki

Gaál‐Paavola, Emília

Perola, Markus

Wennerberg, Krister

Vik‐Mo, Einar O.
Funding

Funding for this research was provided by:

Kreftforeningen (144402)

Kreftforeningen (144402)
License Information

Version of Record valid from 2019-12-30

Text and Data Mining valid from 2019-12-01
More Information

Article History

Received: 3 November 2019

Accepted: 19 December 2019

First Online: 30 December 2019

Ethics approval and consent to participate

: The Norwegian Regional Committee for Medical Research Ethics (REK 07321b, 2017/167) approved all procedures performed in studies involving human participants. Written informed consent was obtained from all individual participants included in the study. The National Animal Research Authority approved all animal procedures (FOTS 8318).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current